Parsons Capital Management Inc. RI grew its position in Amgen, Inc. (NASDAQ:AMGN) by 1.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 22,625 shares of the medical research company’s stock after purchasing an additional 331 shares during the period. Parsons Capital Management Inc. RI’s holdings in Amgen were worth $4,176,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. All Terrain Financial Advisors LLC boosted its holdings in shares of Amgen by 5.1% in the second quarter. All Terrain Financial Advisors LLC now owns 6,746 shares of the medical research company’s stock valued at $1,245,000 after acquiring an additional 326 shares in the last quarter. Martingale Asset Management L P lifted its stake in Amgen by 63.8% during the second quarter. Martingale Asset Management L P now owns 33,378 shares of the medical research company’s stock valued at $6,162,000 after purchasing an additional 12,998 shares during the last quarter. Motco lifted its stake in Amgen by 1.5% during the second quarter. Motco now owns 27,682 shares of the medical research company’s stock valued at $5,110,000 after purchasing an additional 412 shares during the last quarter. Vista Capital Partners Inc. acquired a new stake in Amgen during the second quarter valued at approximately $208,000. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors acquired a new stake in Amgen during the second quarter valued at approximately $269,000. Hedge funds and other institutional investors own 77.23% of the company’s stock.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction that occurred on Monday, July 16th. The shares were sold at an average price of $195.71, for a total value of $298,457.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.19% of the stock is owned by corporate insiders.

AMGN stock opened at $200.35 on Friday. Amgen, Inc. has a 12-month low of $163.31 and a 12-month high of $201.23. The company has a debt-to-equity ratio of 2.03, a current ratio of 3.39 and a quick ratio of 3.12. The company has a market capitalization of $128.56 billion, a price-to-earnings ratio of 15.93, a P/E/G ratio of 1.94 and a beta of 1.36.

Amgen (NASDAQ:AMGN) last released its earnings results on Thursday, July 26th. The medical research company reported $3.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.52 by $0.31. Amgen had a net margin of 10.19% and a return on equity of 43.18%. The company had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $5.73 billion. During the same quarter in the prior year, the firm earned $3.27 EPS. The company’s revenue was up 4.3% compared to the same quarter last year. research analysts expect that Amgen, Inc. will post 13.95 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 7th. Shareholders of record on Friday, August 17th will be given a $1.32 dividend. The ex-dividend date of this dividend is Thursday, August 16th. This represents a $5.28 dividend on an annualized basis and a yield of 2.64%. Amgen’s payout ratio is 41.97%.

AMGN has been the subject of several recent research reports. Cann reissued a “buy” rating and set a $224.00 target price on shares of Amgen in a research note on Monday, July 30th. BidaskClub raised shares of Amgen from a “sell” rating to a “hold” rating in a research note on Friday, May 25th. Oppenheimer reissued a “buy” rating and set a $224.00 target price on shares of Amgen in a research note on Tuesday. Mizuho set a $200.00 target price on shares of Amgen and gave the company a “buy” rating in a research note on Tuesday, May 15th. Finally, Goldman Sachs Group restated a “buy” rating and issued a $228.00 price target on shares of Amgen in a research report on Friday, July 27th. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating and twelve have issued a buy rating to the company. Amgen presently has a consensus rating of “Hold” and a consensus target price of $202.76.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.

Read More: Asset Allocation Models, Which is Right For You?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.